Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for PHARMARON?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥1.63B in FY2016 to CN¥14.10B in FY2025 (9-year CAGR +27.0%).
- Profitable in every fiscal year across 2016–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 7.44 | 10.3 | 11.5 | 12.3 | 14.1 |
| YoY | 45.0% | 37.9% | 12.4% | 6.4% | 14.8% |
| Net Income (CNY B) | 1.66 | 1.37 | 1.60 | 1.79 | 1.66 |
| YoY | 41.7% | -17.2% | 16.5% | 12.0% | -7.2% |
| Operating Cash Flow (CNY B) | 2.06 | 2.14 | 2.75 | 2.58 | 3.22 |
| ROE | 17.5% | 13.3% | — | 13.2% | 11.6% |
| Gross Margin | 35.9% | 36.5% | 35.5% | 33.8% | 34.5% |
| Net Margin | 22.3% | 13.4% | 13.9% | 14.6% | 11.8% |
| Debt-to-Assets | 44.0% | 47.1% | — | 40.6% | 41.9% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 1.63 | 2.29 | 2.91 | 3.76 | 5.13 | 7.44 | 10.3 | 11.5 | 12.3 | 14.1 |
| YoY | — | 40.4% | 26.8% | 29.2% | 36.6% | 45.0% | 37.9% | 12.4% | 6.4% | 14.8% |
| Net Income (CNY B) | 0.17 | 0.22 | 0.34 | 0.55 | 1.17 | 1.66 | 1.37 | 1.60 | 1.79 | 1.66 |
| YoY | — | 29.9% | 51.0% | 62.8% | 114.3% | 41.7% | -17.2% | 16.5% | 12.0% | -7.2% |
| Operating Cash Flow (CNY B) | 0.26 | 0.59 | 0.79 | 0.94 | 1.65 | 2.06 | 2.14 | 2.75 | 2.58 | 3.22 |
| ROE | 9.7% | 11.9% | 15.6% | 10.9% | 14.1% | 17.5% | 13.3% | — | 13.2% | 11.6% |
| Gross Margin | 30.5% | 33.8% | 32.6% | 35.4% | 37.3% | 35.9% | 36.5% | 35.5% | 33.8% | 34.5% |
| Net Margin | 10.5% | 9.7% | 11.6% | 14.6% | 22.8% | 22.3% | 13.4% | 13.9% | 14.6% | 11.8% |
| Debt-to-Assets | 39.6% | 51.8% | 51.6% | 21.1% | 25.0% | 44.0% | 47.1% | — | 40.6% | 41.9% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Watch
-
Watch
Short-Term Debt CoverageSolvency
Cash CN¥3.01B, short-term debt CN¥4.79B (0.63x)
Q3 (2026-09-30) · What is this?
-
Watch
Profit WarningMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.229 per share, or 0.78% yield at closing price; last full fiscal year: HK$0.229 (payout ratio 21.0%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.